Clinical Trials Logo
  1. Home
  2. Myxoid Liposarcoma
  3. NCT00633165

Brostallicin Clinical Trial for Myxoid Liposarcoma — SMI-BRS-202  

Myxoid Liposarcoma Clinical Trial

Official title:
A Phase II, Multicenter Study to Explore the Efficacy and Safety of Brostallicin in Patients With Myxoid Liposarcoma With (12:16) Translocation

Clinical Trial Summary

This is a Phase II, multicenter, open-label clinical trial designed to determine the efficacy and safety of Brostallicin when administered once every 3 weeks in patients with myxoid liposarcoma with (12;16) translocation. The primary objective of this study is to determine the response rate following Brostallicin administration.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00633165
Study type Interventional
Source Systems Medicine LLC
Contact
Status Active, not recruiting
Phase Phase 2
Start date August 2007
Completion date June 2010
View Details
See also
  Status Clinical Trial Phase
Terminated NCT01957709 - Recombinant Interferon Gamma in Treating Patients With Soft Tissue Sarcoma Early Phase 1
Active, not recruiting NCT03600649 - Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas Phase 1
Completed NCT02821507 - Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and Chondrosarcoma Phase 2
Withdrawn NCT03397186 - Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma Phase 2
Active, not recruiting NCT03989596 - Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas Phase 2
Recruiting NCT04699292 - International Prospective Registry on Local Treatment Approaches in MLS
Enrolling by invitation NCT05266196 - A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577) Phase 1/Phase 2
Recruiting NCT05492682 - START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer Phase 1
Active, not recruiting NCT03651375 - Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall Phase 2
Recruiting NCT04044768 - Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma Phase 2
Active, not recruiting NCT03816475 - Hypofractionated Radiotherapy in Locally Advanced Myxoid Liposarcomas of Extremities or Trunk Wall (LIPO-MYX Trial) Phase 2